Esperion Says FDA Stance Means No Clear Regulatory Path For ETC-1002

Esperion Therapeutics and the FDA have failed to reach agreement on a definitive approval path for the company's cholesterol drug ETC-1002, raising the possibility of a long and more expensive development pathway for the oral therapy.